Lymphoma Clinical Trials

Evaluation of Enhanced Gastrointestinal Cancer Screening in Lymphoma Survivors Treated with Prior Radiation Therapy

Lymphoma survivors who were treated with prior radiation therapy have been shown to have an increased risk of cancers of the gastrointestinal system.

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.

UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma

This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)

UPCC 45418: An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib in Combination with Everolimus in Subjects with Relapsed/Refractory Classical Hodgkin Lymphoma

The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.

UPCC 39418: A Phase II Single Arm Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) In Adult Patients with Refractory or Relapsed Follicular Lymphoma

To evaluate the efficacy of tisagenlecleucel therapy among adult patients with refractory or relapsed follicular lymphoma as measured by complete response rate determined by Independent Review Committee in the full analysis set based on Lugano 2014 classification response criteria.

Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …

A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®.

UPCC 34418: A phase Ib multicenter study to determine the safety and tolerability of tisagenlecleucel in combination with ibrutinib in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma

The purpose of the study is to find out if an engineered T-cell therapy (tisagenlecleucel) in combination with ibrutinib is safe and tolerable for people with relapsed and/or refractory diffuse large B-cell lymphoma.

UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

TBD

None